Peptilogics Revenue and Competitors

Location

$117M

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Peptilogics's estimated annual revenue is currently $2.5M per year.(i)
  • Peptilogics's estimated revenue per employee is $91,000
  • Peptilogics's total funding is $117M.

Employee Data

  • Peptilogics has 27 Employees.(i)
  • Peptilogics grew their employee count by -13% last year.

Peptilogics's People

NameTitleEmail/Phone
1
Founder | President | CEOReveal Email/Phone
2
Chief Strategy OfficerReveal Email/Phone
3
Chief Technology OfficerReveal Email/Phone
4
Chief Strategy OfficerReveal Email/Phone
5
Sr. VP, Regulatory Affairs and QualityReveal Email/Phone
6
VP, CMC and Technical OperationsReveal Email/Phone
7
SVP, Corporate Operations and FinanceReveal Email/Phone
8
VP PeopleReveal Email/Phone
9
VP, CMC and Technical OperationsReveal Email/Phone
10
VP Program DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.6M44-2%N/AN/A
#2
$98.8M6087%N/AN/A
#3
$15M11551%N/AN/A
#4
$13.5M10441%N/AN/A
#5
$0.9M120%N/AN/A
#6
$0.1M7-12%$21.3MN/A
#7
$25.7M180-27%N/AN/A
#8
$15.5M119-13%$5.3MN/A
#9
$2.6M29-34%N/AN/A
#10
$1.3M17N/AN/AN/A
Add Company

What Is Peptilogics?

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

keywords:N/A

$117M

Total Funding

27

Number of Employees

$2.5M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Peptilogics News

2022-04-17 - Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022

Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID...

2022-04-17 - Peptilogics proposed treatment for joint infection moves ...

Peptilogics' research finds that PLG0206 is able to tackle gram-positive and gram-negative pathogens as a bactericidal, broad-spectrum treatment...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.7M2759%N/A
#2
$3.9M2723%N/A
#3
$6.7M27-10%N/A
#4
$2.7M27N/AN/A
#5
$5.4M27-4%N/A